Study to Investigate the Efficacy and Safety of Apomivir®

Apomivir® is extracted from a proprietary spirulina strain, FEM-101, a kind of blue cyanobacterium with patented freeze-thaw lysis and extraction method. According to the preclinical studies, Apomivir® have been proven to have excellent broad-spectrum anti-viral ability, especially for seasonal influenza viruses (Influenza virus A and B) that may cause illness, paralysis and even death, especially in children and elderly people. This phase II study is designed to evaluate the efficacy and safety of Apomivir® (120 mg b.i.d.) in subjects with seasonal influenza.

NCT Number	NCT01677689
Lead Sponsor	Far East Bio-Tec Co., Ltd
Conditions	Influenza
Enrollment	196 participants
Start Date	2026-05-31
Primary Completion	2027-05-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-05-14